Titles
- ANDA submissions--amendments to abbreviated new drug applications under GDUFA1
- Abortion coverage in the ACA marketplace plans: the impact of proposed rules for consumers, insurers and regulators1
- Abortion coverage in the Bipartisan Health Care Stabilization Act of 2018 (S.1771)1
- Abortion coverage in the Premium Relief Act of 2017 (HR 4666)1
- Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report1
- Acceptance and filing reviews for premarket approval applications (PMAs): guidance for industry and Food and Drug Administration staff1
- Access to health insurance1
- Accountability in the Medi-Cal managed care program1
- Accounting for Social Security claiming behavior1
- Achieving care integration for children with medical complexity: the human-centered design approach to care coordination1
- Achieving the greatest impact on health and cost outcomes: focus on reinvesting in social services1
- Acne vulgaris: establishing effectiveness of drugs intended for treatment1
- Adapted value assessment methods for high-impact “single and short-term therapies” (SSTs)1
- Adapting verification processes to prevent wrong radiology events1
- Adaptive designs for clinical trials of drugs and biologics1
- Additive therapies for cardiovascular disease: final policy recommendations1
- Addressing health and social needs of immigrant families: lessons from local communities1
- Adequate premium tax credits are vital to maintain access to affordable health coverage for older adults1
- Administering work-related requirements across human services programs: service delivery approaches1
- Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff1